



Selected Protocols for the Treatment of Pediatric Cancer and Blood Disorders

This listing changes frequently.

It also does not include most of our Children's Oncology Group (COG) trials.

We are part of the COG Phase 1 Consortium – one of only 21 centers nationally, and the only one in New England. For more information about the trials we have available, please contact clinicaltrials@danafarberbostonchildrens.org

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
EXPERIMENTAL THERAPEUTICS – early phase trials for patients with SOLID TUMORS, BRAIN TUMORS, AND/OR LYMPHOMA/LEUKEMIA			
Relapsed/Refractory Solid Tumors, CNS Tumors and Lymphoma	Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma	16-371/I	Steven DuBois, MD, MS 617- 632-4450
Relapsed Refractory CNS and Solid Tumors	A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	15-467/I	Susan Chi, MD 617-632-4386
Relapsed Refractory CNS and Solid Tumors, including Neuroblastoma and Lymphoma	A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors	16-094/I-II	Steven DuBois, MD, MS 617-632-4450
Relapsed Refractory CNS and Solid Tumors	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors	16-045/I-Ib	Suzanne Shusterman, MD 617-632-4901
Relapsed/ Refractory Solid Tumors and CNS Tumors	A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/ Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors	16-196/I	Steven DuBois, MD, MS 617-632-4450
Relapsed Refractory Solid Tumors and Lymphoma	A Phase 1/2 Study of Nivolumab (Ind# 124729) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab (ADVL1412)	16-722/I-II	Steven DuBois, MD, MS 617-632-4450
Relapsed/ Refractory Medulloblastoma and Neuroblastoma	A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors (ADVL1312)	16-447/I-II	Steven DuBois, MD, MS 617-632-4450
Relapsed Refractory CNS and Solid Tumors	A Phase I Study of Selinexor (KPT-330, IND 125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors (ADVL1414)	15-718/I	Suzanne Shusterman, MD 617-632-4901

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
EXPERIMENTAL THERAPEUTICS (continued)			
Relapsed Refractory CNS and Solid Tumors	A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers	17-481	Steven DuBois, MD, MS 617-632-4450
Relapsed/ Refractory Solid Tumors, Leukemia and Lymphoma	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies	17-617	Andrew Place, MD, PhD
Relapsed Refractory Solid Tumors, including CNS and Lymphoma	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors.	17-746	Steven DuBois, MD, MS 617-632-4450
Relapsed Refractory Solid Tumors	ADVL 1614 A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors	18-704	Steven DuBois, MD, MS 617-632-4450
Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	A Phase I Study of AZE1775 Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas (ADVL1217)	17-122/I	Steven DuBois, MD, MS 617-632-4450
Relapsed/Refractory Solid Tumors, CNS Tumors and Lymphoma	A Phase I Study of Entinostat, an Oral Histone Deacetylase Inhibitor, In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (ADVL 1513)	17-700/I	Steven DuBois, MD, MS 617-632-4450
Relapsed/Refractory Solid Tumors and CNS Tumors	A Phase I Study of LY2606368, a CHK1/2 Inhibitor in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors (ADVL 1515)	17-703/I	Steven DuBois, MD, MS 617-632-4450
Relapsed/ Refractory Solid Tumors and CNS Tumors	A Phase 1 Study of ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan (ADVL1514)	17-728/I	Steven DuBois, MD, MS 617-632-4450
Relapsed/Refractory Solid Tumors, CNS Tumors and Lymphoma	NCI-COG Pediatric MATCH Molecular Analysis for Therapy Choice Protocol (APEC1621)	17-729	Katherine Janeway, MD 617-632-4994
Relapsed/Refractory Solid Tumors and CNS Tumors	A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors	17-703	Steven DuBois, MD, MS 617-632-4450
Relapsed/Refractory Solid Tumors and CNS Tumors	A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors	17-513	Steven DuBois, MD, MS 617-632-4450
Relapsed/Refractory Solid Tumors and CNS Tumors Relapsed/Refractory Solid Tumors and CNS Tumors	ADVL1514, A Phase 1 Study of ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and In Combination with Temozolomide and Irinotecan	17-728	Steven DuBois, MD, MS 617-632-4450
Relapsed/Refractory Low Grade Gliomas and other Solid Tumors	A Phase I/II Study of MEK162 for Children Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors	15-368/I-II	Karen Wright, MD 617-632-4386

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
EXPERIMENTAL THERAPEUTICS (continued)			
Relapsed/ Refractory Solid Tumors and Leukemia	Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias	15-588/I	Steven DuBois, MD, MS 617-632-4450
Relapsed/ Refractory Solid Tumors and CNS Tumors	A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors	15-524/I-II	Steven DuBois, MD, MS 617-632-4450
Relapsed Refractory CNS, Solid Tumors and Lymphoma	A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (ADV1621)	16-235/I-II	Steven DuBois, MD, MS 617-632-4450
Relapsed/ Refractory Solid Tumors and CNS Tumors	A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors (ADV11312)	16-447/I-II	Steven DuBois, MD, MS 617-632-4450
Relapsed Refractory Neuroectodermal Tumors, Rhabdomyosarcoma and/ or Other Solid Tumors	A Phase I Open Label, Dose Escalation Trial to Determine the MTD, Safety, PK and Efficacy of Afatinib Monotherapy in Children Aged 2 Years to <18 Years with Recurrent/Refractory Neuroectodermal Tumors, Rhabdomyosarcoma and/or Other Solid Tumors with Known ErbB Pathway Deregulation Regardless of Tumor Histology	15-315/I	Karen Wright, MD 617-632-4386
Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)	Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents	16-001/III	Lewis Silverman, MD 617-632-6191
Infant Acute Lymphoblastic Leukemia (ALL)	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with ALL and KMT2A(MLL) Gene Expression (AALL15P1)	17-714	Lewis Silverman, MD 617-632-6191
Relapsed Leukemia (ALL and AML) (Relapsed/ Refractory)	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	13-563/I	Andrew Place, MD, PhD 617-632-2313
Relapsed ALL and NHL	A Phase I Trial of Temsirolimus in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma	15-213/I	Lewis Silverman, MD 617-632-6191
Relapsed AML	A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myelogenous Leukemia (AAML1421)	16-717/I-II	Andrew Place, MD, PhD 617-632-2313
Relapsed ALL	T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia	16-568/Pilot	Andrew Place, MD, PhD 617-632-2313
Leukemia Recurrent/Refractory	Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias	15-384	Yana Pikman, MD 617-632-4754

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
EXPERIMENTAL THERAPEUTICS (continued)			
Recurrent/Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	A Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	15-005/II	Barbara Degar, MD 617-632-5186
Hemophagocytic Lymphohistiocytosis (HLH) (Reactivated)	A Pilot, Open-Label, Single Arm, Multicenter Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-Interferon Gamma (Anti-IFN γ) Monoclonal Antibody, in Pediatrics Patients with Primary HLH Which Has Reactivated	14-018	Barbara Degar, MD 617-632-5186
Hodgkin Lymphoma (High Risk)	Brentuximab Vedotin Substituting Vincristine in the OEPA/ COPDAC Regimen with Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma	14-233/II	Amy Billett, MD 617-632-5640
Langerhans Cell Histiocytosis (LCH)	International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	13-428	Barbara Degar, MD 617-632-5186
Leukemia (AML) (Relapsed/ Refractory)	Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study	15-581	Andrew Place, MD, PhD 617-632-2313
HEMATOLOGIC MALIGNANCIES			
Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)	Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents	16-001/III	Lewis Silverman, MD 617-632-6191
Infant Acute Lymphoblastic Leukemia (ALL)	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with ALL and KMT2A(MLL) Gene Expression (AALL15P1)	17-714	Lewis Silverman, MD 617-632-6191
Relapsed Leukemia (ALL and AML) (Relapsed/ Refractory)	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	13-563/I	Andrew Place, MD, PhD 617-632-2313
Relapsed ALL and NHL	A Phase I Trial of Temsirolimus in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma	15-213/I	Lewis Silverman, MD 617-632-6191
Relapsed AML	A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myelogenous Leukemia (AAML1421)	16-717/I-II	Andrew Place, MD, PhD 617-632-2313
Relapsed ALL	T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo $\text{\textcircled{R}}$) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia	16-568/Pilot	Andrew Place, MD, PhD 617-632-2313
Leukemia Recurrent/Refractory	Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias	15-384	Yana Pikman, MD 617-632-4754

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
HEMATOLOGIC MALIGNANCIES (continued)			
Recurrent/Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	A Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	15-005/II	Barbara Degar, MD 617-632-5186
Hemophagocytic Lymphohistiocytosis (HLH) (Reactivated)	A Pilot, Open-Label, Single Arm, Multicenter Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-Interferon Gamma (Anti-IFN γ) Monoclonal Antibody, in Pediatrics Patients with Primary HLH Which Has Reactivated	14-018	Barbara Degar, MD 617-632-5186
Hodgkin Lymphoma (High Risk)	Brentuximab Vedotin Substituting Vincristine in the OEPA/ COPDAC Regimen with Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma	14-233/II	Amy Billett, MD 617-632-5640
Langerhans Cell Histiocytosis (LCH)	International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	13-428	Barbara Degar, MD 617-632-5186
Leukemia (AML) (Relapsed/ Refractory)	Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study	15-581	Andrew Place, MD, PhD 617-632-2313
NON-MALIGNANT HEMATOLOGY			
Aplastic Anemia	Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT) PBMTc NMD1601	P00021716	Akiko Shimamura, MD, PhD 617-919-6109
Bone Marrow Failure/ Myelodysplastic Syndrome	Molecular and Genomic Studies of Bone Marrow Failure and Myelodysplastic Syndrome	P00024102	Akiko Shimamura, MD, PhD 617-919-6109
Bone Marrow Failure/ Myelodysplastic Syndrome	North American Shwachman-Diamond Syndrome Registry and Study	P00020456	Akiko Shimamura, MD, PhD 617-919-6109
Pyruvate Kinase Deficiency (PKD)	A Phase 2a, Open Label, Randomized, Dose Regime, Safety, Efficacy, Pharmacokinetics and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency (PKD) (AG348-C-003)	P00016857/II	Rachael Grace, MD, MMSc 617-919-2144
Fanconi Anemia	Pilot Study of Metformin for Patients with Fanconi Anemia	P00026540	Akiko Shimamura, MD, PhD 617-919-6109
Hemophilia	A Longitudinal, Prospective Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Factor Preparations	P00019137	Stacy Croteau, MD, MMS 617-919-2139
Hemophilia	PK-Tailored Approach to Prophylaxis Feasibility	P000026036	Stacy Croteau, MD, MMS 617-919-2139
Hemophilia	CDC Public Health Surveillance for Bleeding Disorders-Registry for Bleeding Disorders	P00009826	Stacy Croteau, MD, MMS 617-919-2139

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
NON-MALIGNANT HEMATOLOGY (continued)			
Sickle Cell Disease	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease	P0017292/III	Matthew Heeney, MD 617-355-7700
Thrombosis	A Randomized, Open-Label, Active Controlled, Safety and Extrapolated Efficacy Study of apixaban in Pediatric Patients Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event (B0661037/CV185-325)	P00016074	Rachael Grace, MD, MMSc 617-919-2144
Thrombosis	Phase IIb/III Open-label, randomized, parallel-group, active-controlled, multicenter, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birth to less than 18 years of age.	P00016492	Stacy Croteau, MD, MMS 617-919-2139
Thrombosis	Phase III, Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years	P00022205	Stacy Croteau, MD, MMS 617-919-2139
VASCULAR ANOMALIES			
Vascular Anomalies	A Randomized Phase 2 Study of Vincristine vs. Sirolimus to treat High Risk Kaposiform Hemangioendothelioma – SIR-DA-1202	P00013131	Denise Adams, MD 617-355-5226
Vascular Anomalies	Study of ARQ092 in PIK3CA – Related Overgrowth and Vascular Anomalies	P00023580	Denise Adams, MD 617-355-5226
Vascular Anomalies	Lymphatic Anomalies Registry	P00007182/II	Denise Adams, MD 617-355-5226
STEM CELL TRANSPLANTATION			
Stem Cell Transplantation (Dyskeratosis Congenita)	Non-TBI and Alkylator-Free Conditioning for Allogeneic Bone Marrow Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease	P00003466	Suneet Agrawal, MD 617-919-4610
Stem Cell Transplantation (Bone Marrow Failure)	A Phase II Dose-Escalation Study Characterizing the PK of Eltromopag in Pediatric Patients with Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia	P00025436	Akiko Shimamura, MD, PhD 617-919-6109
Stem Cell Transplantation (Hematologic Malignancies)	Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies	13-042/II	Christine Duncan, MD 617-632-4882
Stem Cell Transplantation	Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies	16-535	Jennifer Whangbo, MD, PhD 617-632-2664
Stem Cell Transplantation (Cord Blood Unit Access)	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUS) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications	11-297	Leslie Lehmann, MD 617-632-4882

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
STEM CELL TRANSPLANTATION (continued)			
Stem Cell Transplantation (Gut decontamination)	A Randomized Phase 2 Study to Examine the Impact of Gut Decontamination on Intestinal Microbiome Composition in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients	15-394/II	Jennifer Whangbo, MD, PhD 617-632-2664
Stem Cell Transplantation (Transfusion -dependent Beta Thalassemia)	ST- 400 for Autologous Hematopoietic Stem Cell Transplant for the Treatment of Transfusion-Dependent Beta Thalassemia	P00027470	Alessandra Biffi, MD 617-632-2185
CELL AND GENE THERAPY FOR RARE DISEASES			
Childhood Cerebral Adrenoleukodystrophy (CCALD)	A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced with Lenti-D Lentiviral Vector for the Treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)	P00007954/ II-III	David A. Williams, MD 617-919-2697
Severe Combined Immuno-Deficiency Syndrome (SCID)	Gene Transfer for SCID-X1 Using a Self-Activating (SIN) Gammaretroviral Vector	09-05-0254	Sung-Yun Pai, MD 617-919-2508
X-Linked Chronic Granulomatous Disease (CGD)	A Phase I/II, Non-Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-Linked CGD	P00012407/I-II	David A. Williams, MD 617-919-2697
Wiskott-Aldrich Syndrome	Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome	P00000148	Sung-Yun Pai, MD 617-919-2508
Sickle Cell Disease	Gene Transfer for Sickle Cell Disease	P00002452	Erica Esrick, MD 617-355-2569
SOLID TUMORS			
Solid Tumors Recurrent/Refractory	Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Recurrent, Refractory, or High Risk Solid Tumors: The iCat2, GAIN Consortium Study	15-169	Katherine Janeway, MD 617-632-4994
Solid Tumors (Relapsed/Refractory)	Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors	17-716	Suzanne Shusterman, MD 617-632-4901
Solid Tumors (Recurrent Ewing's Sarcoma)	Phase I Study of Olaparib with Irinotecan and/or Temozolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing's Sarcoma following failure of prior chemotherapy	13-115/I	Steven DuBois, MD, MS 617- 632-4450
Solid Tumors (Relapsed/Refractory Sarcoma)	Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma	17-199/I	Steven DuBois, MD, MS 617-632-4450
Neuroblastoma, (Relapsed/ Refractory)	A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory or Recurrent Neuroblastoma. (NANT N2011-04)	12-505/I	Suzanne Shusterman, MD 617-632-4901

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
SOLID TUMORS (continued)			
Neuroblastoma Relapsed/Refractory	NANT 2014-01: Phase 1 Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma	15-243/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma Relapsed/Refractory	NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/ Topotecan in Patients with Relapsed and Refractory Neuroblastoma	14-494/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma Relapsed/Refractory	NANT 2015-02 Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients with ALK-Driven Relapsed or Refractory Neuroblastoma	17-393	Suzanne Shusterman, MD 617-632-4901
Malignant Germ Cell Tumors	A Phase II Study of Sirolimus & Erlotinib in Recurrent/Refractory Malignant Germ Cell Tumors	14-134/II	Lindsay Frazier, MD 617-632-2237
BRAIN TUMORS			
Medulloblastoma (Newly Diagnosed Wnt Positive)	Pilot Study of Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma	14-252/Pilot	Pratiti Bandopadhyay, MBBS, PhD 617-632-4309
Brain Tumors (Newly Diagnosed)	Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies	17-221/Ib-II	Karen Wright, MD 617-632-4386
Low Grade Glioma (Previously Untreated)	A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma	15-117/III	Karen Wright, MD 617-632-4386
Diffuse Intrinsic Pontine Glioma (DIPG) (Newly Diagnosed)	PNOC 007: H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas	16-619/Pilot	Susan Chi, MD 617-632-4386
Brain Tumors (Relapsed/ Refractory Low Grade Gliomas)	PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Glioma in Children	15-369/II	Susan Chi, MD 617-632-4386
Brain Tumors (Recurrent/Progressive Supratentorial tumors and DIPG post XRT)	A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects	17-337	Susan Chi, MD 617-632-4386
Medulloblastoma (Recurrent/Refractory)	A Phase II Study of Metronomic and Targeted Anti-Angiogenesis Therapy for Children with Refractory/Recurrent Medulloblastoma	13-359/II	Susan Chi, MD 617-632-4386
Brain Tumors (Relapsed/ Refractory)	PNOC 002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E or BRAF Ins T mutant Brain Tumors	16-234/Pilot	Susan Chi, MD 617-632-4386
Brain Tumors (Relapsed/ Refractory)	A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain Tumors	17-227/II	Susan Chi, MD 617-632-4386

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
BRAIN TUMORS (continued)			
Brain Tumors (Recurrent Glioblastoma)	INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group / Evaluation of ABT-414 in Children with High Grade Gliomas	16-543/II	Karen Wright, MD 617-632-4386
Brain Tumors (Recurrent Medulloblastoma or Recurrent ATRT)	PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)	17-103	Susan Chi, MD 617-632-4386
Brain Tumors (Relapsed/Refractory HGG)	Phase 2 Open-Label Global Study to Evaluate the Effect of Dabrafenib in Combination with Trametinib in Children and Adolescent Patients with BRAF V600 Mutation Positive Relapsed or Refractory High Grade Glioma (HGG)	17-532	Susan Chi, MD 617-632-4386

Dana-Farber/Boston Children's Cancer and Blood Disorders Center represents the integrated pediatric oncology program at Dana-Farber Cancer Institute and Boston Children's Hospital. The more than 60-year-old program offers comprehensive care to children, adolescents, young adults, and survivors of all types of childhood cancers and related blood diseases.